Liehua Liu

Prof. Liehua Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2014 in Diabetologia
Verified
Journal Article
Open access
PDF file
BOBilal A. Omar
Bilal A. Omar
LLLiehua Liu
Liehua Liu
YYYuchiro Yamada
Yuchiro Yamada
YSYutaka Seino Yutaka Seino
Yutaka Seino Yutaka Seino
PMPiero Marchetti
Piero Marchetti
BABo Ahren
Bo Ahren
Inhibition of the enzyme dipeptidyl peptidase 4 (DPP-4), which cleaves and inactivates glucagon-like peptide 1 (GLP-1), is a glucose-lowering strategy in type 2 diabetes. Since DPP-4 is a ubiquitously distributed enzyme, we examined whether it is expressed in islets and whether an islet effect to inhibit DPP-4 may result in stimulated insulin secretion.

15 October 2024 in BMJ
Verified
Journal Article
Open access
PDF file
LLLiehua Liu
Liehua Liu
WKWeijian Ke
Weijian Ke
HLHai Li
Hai Li
FLFangping Li
Fangping Li
GFGuanjie Fan
Guanjie Fan
YLYanbing Li
Yanbing Li
Objective: To evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia. Design: Multicentre, open label, randomised trial. Setting: 15 hospitals in China between December 2017 and December 2020. Participants: 412 patients with newly diagnosed type 2 diabetes and significant hyperglycaemia (HbA 1c ≥8.5%). Interventions: All randomised participants initially received SIIT for 2-3 weeks, followed by linagliptin 5 mg/day, metformin 1000 mg/day, combination linagliptin plus metformin, or lifestyle modification alone (control) for 48 weeks. Main outcome measures: The primary outcome was the percentage of participants achieving HbA 1c <7.0% at week 48 after SIIT. Secondary outcomes included glycaemic control, β cell function, and variations in insulin sensitivity. Results: 412 participants were randomised. At baseline, the mean age was 46.8 (standard deviation 11.2) years, mean body mass index was 25.8 (2.9), and mean HbA 1c was 11.0% (1.9%). At week 48, 80% (78/97), 72% (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieved HbA 1c <7.0%, compared with 60% (56/93) in the control group (P=0.02 overall; P=0.003 for linagliptin plus metformin versus control; P=0.12 for linagliptin versus control; P=0.09 for metformin versus control). Additionally, 70% (68/97), 68% (60/88), and 68% (65/95) of patients in the linagliptin plus metformin, linagliptin, and metformin group, respectively, achieved HbA 1c <6.5% compared with 48% (45/93) in the control group (P=0.005 overall; P=0.005 for linagliptin plus metformin versus control; P=0.01 for linagliptin versus control; P=0.008 for metformin versus control; all were significant after adjustment for multiple comparisons). Thus, compared with the control group, participants in the linagliptin plus metformin group were more likely to achieve HbA 1c <7.0% at week 48 (odds ratio 2.78, 95% confidence interval 1.37 to 5.65; P=0.005). Moreover, the linagliptin plus metformin group showed the most significant improvement in fasting plasma glucose and β cell function indices. All treatments were well tolerated. Conclusions: The intense simplified strategy using subsequent oral therapies post-SIIT, especially the linagliptin plus metformin combination, sustainably improved glycaemic control and β cell function in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia. This approach offers a promising direction for decision making in the clinical management of type 2 diabetes mellitus. Trial registration: ClinicalTrials.gov NCT03194945

16 May 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
WYWenjing Ye
Wenjing Ye
LXLijuan Xu
Lijuan Xu
YYYanbin Ye
Yanbin Ye
FZFangfang Zeng
Fangfang Zeng
XLXin Lu
Xin Lu
LLLiehua Liu
Liehua Liu
Meal replacement (MR) is beneficial for management of Type 2 Diabetes (T2D). However, MR prescription and patient characteristics varied significantly between studies using MR in T2D patients. Objective To evaluate the efficacy and safety of MR in T2D patients by meta-analysis, with a focus on subgroup analysis of variable participant characteristics and MR prescription. Methods We searched Pubmed, CENTRAL, Embase, Web of science, and the clinical trial registration database up to March 2022. We included randomized trials of ≥ 2 weeks assessing the effect and safety of MR in T2D patients in comparison with conventional diabetic diets (CDs). Results 17 randomized controlled trials (RCTs) involving 2112 participants were ultimately included. Compared with CDs, MR significantly reduced HbA1c (MD -0.46%, P < 0.001), fasting blood glucose (FBG, -0.62 mmol/L, P < 0.001), body weight (-2.43 kg, P < 0.001) and BMI (-0.65 kg/m2, P < 0.001), and improved other cardiometabolic risk factors. In subgroup analyses, total MR showed greater improvement in HbA1c (-0.72% vs. -0.32%, P = 0.01), FBG (-1.45 vs. -0.56 mmol/L, P = 0.02), body weight (-6.57 vs. -1.58 kg, P < 0.001), and BMI (-2.78 vs. -0.37 kg/m2, P < 0.001) than partial MR. MR with caloric restriction showed more reduction in body weight (-3.20 vs. -0.75 kg, P < 0.001) and BMI (-0.84 vs. -0.24 kg/m2, P = 0.003) compared with those without caloric restriction. MR showed similar benefits in studies that included patients using insulin and those that didn’t. Both partial and total MR were well tolerated. Conclusions Compared with CDs, the MR-based dietary pattern further improved the glycemic control and adipose indicators in T2D patients. Appropriate calorie restriction and total MR might be more beneficial, while both patients treated with or without insulin treatment could similarly benefit from MR usage.

15 November 2018 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
LLLiehua Liu
Liehua Liu
SYSiyue Yang
Siyue Yang
JLJianbin Liu
Jianbin Liu
HLHai Li
Hai Li
JLJuan Liu
Juan Liu
YLYanbing Li
Yanbing Li
Recovery of acute insulin response (AIR) is shown to be associated with long-term outcomes of patients with early type 2 diabetes treated with short-term intensive insulin therapy (SIIT). However, the complexity of measuring an AIR limits its utility in a real-world clinical setting. The aim of the study was to assess fasting indicators that may estimate recovery of the AIR after SIIT. We enrolled 62 patients with type 2 diabetes mellitus (T2DM) of varying disease duration who had poor glycemic control. Participants were treated with SIIT using insulin pumps to achieve near normoglycemia for 7 days. The AIR before and after the therapy were measured by intravenous glucose tolerance tests. After the therapy, AIR increased from −16.7 (−117.4, 52.4) pmol/L·min to 178.7 (31.8, 390.7) pmol/L·min (P<0.001) while hyperglycemia was alleviated; this improvement was observed in all disease duration categories. AIR was almost absent when fasting plasma glucose (FPG) > 10 mmol/L, while both AIR (R=−0.53, P<0.001) and its improvement from baseline (△AIR, R=−0.52, P<0.001) were negatively associated with FPG after SIIT when FPG < 10 mmol/L. In multivariate analyses, FPG after SIIT and baseline fasting C peptide were independent indicators of both AIR after the therapy and ∆AIR; HDL-C after the therapy also predicted AIR after the therapy. We concluded that recovery of the AIR could be obtained in T2DM patients of varying disease duration by SIIT and it could be conveniently estimated using posttreatment fasting plasma glucose and other fasting indicators.

19 February 2020 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
LXLijuan Xu
Lijuan Xu
PZPengyuan Zhang
Pengyuan Zhang
ZHZhimin Huang
Zhimin Huang
LZLiangying Zhong
Liangying Zhong
HLHai Li
Hai Li
YLYanbing Li
Yanbing Li
Background. Short-term intensive insulin therapy induces long-term glycemic remission in half of patients with newly diagnosed type 2 diabetes. The concomitant hypoglycemia needs further analysis. Methods. We collected data from three randomized trials conducted with the same inclusion and exclusion criteria at our institution from 2002 to 2015. Continuous subcutaneous insulin infusion (CSII) was provided to achieve the glycemic goals within a week and then maintained for 14 days. Hypoglycemia episodes during short-term treatment and the one-year drug-free glycemic remission were observed. Results. A total of 244 patients were included. The per day episode of mild hypoglycemia (3.0-3.9 mmol/L) was higher in the remission group than in the nonremission group (0.26±0.20 vs. 0.18±0.21, P=0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02±0.04 vs. 0.03±0.04, P=0.221). After the cessation of insulin treatment, both acute insulin response (491.35 (801.89) vs. 370.22 (542.29), P=0.028) and homeostasis model assessment of insulin resistance (2.08 (2.04) vs. 2.48 (2.32), P=0.038) were more improved in the remission group than in the nonremission group. Logistic regression analysis showed that mild hypoglycemic episodes during short-term CSII treatment were independently related to a long-term glycemic remission (OR=2.18, 95% CI 1.02~4.70). Stratified analysis demonstrated that episodes during the continuing insulin dose reduction period played a substantial role. Conclusions. Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. However, the insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms.

29 July 2019 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
HLHai Li
Hai Li
JLJianbin Liu
Jianbin Liu
JLJuan Liu
Juan Liu
LLLiehua Liu
Liehua Liu
MHMinmin Huang
Minmin Huang
YLYanbing Li
Yanbing Li
The absence of nocturnal blood pressure (BP) decline is associated with hypertensive complications. Data regarding circadian BP patterns in patients with aldosterone-producing adenoma (APA) are limited and equivocal. We evaluated the circadian BP profile in patients with APA and its relationship with the circadian aldosterone rhythm. BP in patients with APA and in those with essential hypertension (EH) were assessed through in-hospital 24-h ambulatory blood pressure monitoring. Over a 24-h in-hospital period, plasma aldosterone levels taken at midnight, 0400, 0800, 1200, 1600, and 2000 h were measured. To evaluate a correlation between BP and hormone rhythm, we included 27 patients with APA (APA group) and 27 patients with EH (EH group). Both groups had similar age, sex ratio, body mass index, duration of hypertension, family history of hypertension, and lipid profiles. The day-night BP differences in both patient groups were similar, whether expressed as absolute values or percentages. The proportions of patients with dipping BP profiles were also comparable (APA group, 5 of 27; EH group, 7 of 27; χ2 = 0.429; P = 0.513). At each time point, APA group plasma aldosterone concentrations (PACs) were higher than those of the EH group. A circadian change in relation to PAC was observed in both groups. A correlation between PAC and BP was statistically nonsignificant in most study patients in either group. Our data indicated that the circadian BP pattern was not associated with a change in PAC levels in patients with APA.